Loading
Diabetes Treatment and Management · Journal article
Diabetology · August 11, 2026
Encouraging direction, but not yet definitive.
This retrospective cohort study of 202 people living with HIV prescribed GLP-1 or GLP-1/GIP receptor agonists found modest but statistically significant reductions in HbA1c (1.0%), BMI (0.7 kg/m²), and weight (3.55% mean loss) over a mean 24.2 months. Duration of therapy was independently associated with HbA1c reduction >1%, while younger age and absence of insulin use correlated with greater weight loss; the findings are consistent with the known effects of these agents but require prospective confirmation.
Retrospective cohort study. People living with HIV with obesity and/or type 2 diabetes mellitus prescribed GLP-1 receptor agonists or dual GLP-1/GIP receptor agonists at a public hospital in the Bronx, New York; population predominantly Black and Hispanic. Intervention: GLP-1 receptor agonist or dual GLP-1/GIP receptor agonist therapy. n = 202. Single centre: public hospital in the Bronx, New York.
Mean HbA1c reduction of 1.0% (p < 0.001) with GLP-1 or GLP-1/GIP RA therapy Mean BMI reduction of 0.7 kg/m² (p < 0.001) Average mean weight loss of 3.55% over mean 24.2 months of therapy
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
These findings suggest GLP-1 receptor agonists may provide meaningful glycaemic and weight benefits in PLWH, a population vulnerable to weight gain from antiretroviral therapy. However, the retrospective design and single-centre setting limit generalisability; prospective studies are needed before recommending routine use in this population.
Retrospective single-centre study with modest effect sizes (1.0% HbA1c reduction, 3.55% weight loss) in a defined population; real findings needing prospective confirmation in larger cohorts.
As stated by the source record.
Quoted from the source exactly as published.
These findings suggest GLP-1 receptor agonists may provide meaningful glycaemic and weight benefits in PLWH, a population vulnerable to weight gain from antiretroviral therapy. However, the retrospective design and single-centre setting limit generalisability; prospective studies are needed before recommending routine use in this population.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background/Objectives: People living with HIV (PLWH) who undergo prolonged antiretroviral therapy (ART) may experience weight gain as a potential side effect. Many of these individuals are prescribed glucagon-like peptide 1 (GLP-1) receptor agonists (RAs), or dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) RAs, which are known for their weight-reducing effects and positive impact on metabolic health. However, studies investigating their effects on PLWH are limited. Methods: We conducted a retrospective study at a public hospital in the Bronx, New York, among PLWH with obesity and/or type 2 diabetes mellitus (T2DM) prescribed GLP-1 or dual GLP-1/GIP RAs between August 2020 to March 2024. We collected baseline measurements of weight, body mass index (BMI), glycated hemoglobin (HbA1c), and lipid panel, before and after initiation of treatment, to assess the potential metabolic changes associated with the therapy. Logistic regression was used to analyze the factors associated with reductions in HbA1c and weight. Results: A total of 202 patients were included in the final study, with a mean duration of 24.2 months of GLP-1 or GLP-1/GIP RA therapy. A mean HbA1c reduction of 1.0% (p < 0.001), a mean BMI reduction of 0.7 kg/m2 (p < 0.001), and an average mean weight loss of 3.55% were observed. In the univariate analysis, the duration of GLP-1 or GLP-1/GIP RA use was the only factor independently associated with HbA1c reduction greater than 1% (p = 0.027). However, no correlation was found between the duration of their use and the percentage of weight loss (p = 0.126). Insulin use was associated with less weight loss (p = 0.048), while younger age was associated with greater weight loss (p = 0.048). No significant differences in weight loss were observed when the population was stratified by sex, race, comorbidities, type of GLP-1 RA therapy, or other antidiabetic or ART regimens. Conclusions: Use of GLP-1 RAs among PLWH with obesity and/or T2DM is associated with reductions in HbA1c and BMI. In this diverse cohort, which predominantly consists of Black and Hispanic individuals, longer duration of treatment was associated with reductions in HbA1c greater than 1%. These findings encourage GLP-1 RA-related treatment for PLWH with obesity and/or T2DM. Further prospective studies with larger cohorts are needed to confirm these benefits and better define their effects on long-term metabolic health.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.